1. Home
  2. STHO vs INDP Comparison

STHO vs INDP Comparison

Compare STHO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STHO

Star Holdings Shares of Beneficial Interest

HOLD

Current Price

$9.19

Market Cap

120.0M

Sector

Real Estate

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$3.70

Market Cap

125.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STHO
INDP
Founded
2022
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.0M
125.2M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
STHO
INDP
Price
$9.19
$3.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.6K
1.9M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
24.73
N/A
EPS
2.58
N/A
Revenue
$110,143,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.08
$0.92
52 Week High
$9.94
$8.57

Technical Indicators

Market Signals
Indicator
STHO
INDP
Relative Strength Index (RSI) 36.71 71.94
Support Level $9.00 $2.41
Resistance Level $9.16 $3.75
Average True Range (ATR) 0.24 0.41
MACD -0.08 0.27
Stochastic Oscillator 12.50 84.48

Price Performance

Historical Comparison
STHO
INDP

About STHO Star Holdings Shares of Beneficial Interest

Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: